

Figure S1. Increased number of non-viable floating cells following treatment with PBI-05204 plus RT in GBM cells.

А

С

DAP I



Sox-2

(5 µg(ml)

PBI-05204 (1.25 µg(ml)

Merge

Oct3/4

D

basal

PBI + RT

В



RT (4 Gy) stro-1 RT PBI-05204 (2.5 µg/ml) PBI PBI * CTRL CTRL 80 40 60 20 40 0 20 0

Percentage of positive cells

Percentage of positive cells

*

80

60

Figure S2

Figure S2. PBI-05204 enhanced RT mediated suppression of cell proliferation and stemness in U87MG cells. U87MG spheroids were cultured for 3 weeks after administration of 1.25, 2.5 or 5.0 μ g/ml PBI-05204 alone or after a single dose of RT (4 Gy) administered two days after PBI-05204 treatment. (A) Morphologic appearance of U87MG cells grown as neurosphere. Bar (1 cm) correspond to 500 μ m. (B) Count of small (< 20 cells) and large (>20 cells) colonies at 5X magnification (Top). FACS analyses of Ki67 expression in acutaseTM treated single cell suspensions (Bottom, n = 3). Data are represented as mean \pm SD. *p<0.05, ** p<0.01. (C) Confocal analysis of expression of stem cells markers SOX2 and Oct3/4 after the cells were treated with control, RT only, PBI-05204 (2.5 μ g/ml) and combination of RT and PBI-05204 for 96 hrs. Bar represents 25 μ m. (D) The FACS analysis of stro1 and CD44 levels in U87MG cells. Data are presented as mean \pm SE of three separate experiments. *p<0.05, ** p<0.01.

Table S1: Summary of comet assay results analyzed by CaspLab software

U87MG			
Condition	DNA Damage (% DNA in tails)	Tail length (μm)	Total DNA damage (tail moment arbitrary units)
CTRL	4.0 ± 0.5	6.8 ± 0.5	2.5 ± 0.2
RT 1 hr	15.5 ± 5.8*	20.0 ± 2.0*	12.8 ± 4.2*
PBI-05204 1 hr	5.3 ±3.8	15.3 ± 1.5*	5.8 ± 3.0
RT + PBI 1hr	35.5 ± 5.5*	45.5 ± 2.3*	35.4 ± 7.8*
RT 18 hr	28.0 ± 6.0*	53.5 ± 5.5*,a	38.5 ± 4.2*, a
RT + PBI 18 hr	48.0 ± 6.5*, b, **	73.5 ± 10.3*, b.**	55.6 ± 5.8 *
U251			
CTRL	4.0 ± 0.2	3.0 ± 0.5	2.5 ± 0.4
RT 1 hr	9.7 ± 3.0	17.8 ± 2.8*	8.9 ± 2.7*
PBI-05204 1 hr	12.7 ± 0.8*	22.5 ± 6*	5.0 ± 3.5
RT + PBI 1hr	29.0 ± 6.3*	40.9 ± 3.5*	29.7 ± 8*,α
RT 18 hr	19.7.0 ± 5.3*	37.0 ± 8.5*	33.57± 5.6*
RT + PBI 18 hr	52.0 ± 8.7*	58.6 ± 8.6*	60.3 ± 6.4*,b, c

*p<0.01 vs CTRL, ap<0.01 vs PBI or RT alone; b p<0.01 vs RT 18 hr, c p<0.01 vs RT + PBI 1 hr





С



D

U87MG





U251

PBI



PBI+RT

AVO staining (fold increase vs CTRL)











Ε

Figure S3. Combination of PBI-05204 and radiotherapy leads to apoptotic cell death in GBM cells. (A) Representative image of AVO staining performed in U251 cell line treated with RT, PBI-05204 and RT plus PBI-05204. (B) Quantitation of Acridine Orange Staining (AVO) performed in U87MG cells treated with different doses of RT (0-6 Gy) and PBI-05204 (1-20 μ g/ml). AVO accumulation was measured by the fold increase/decrease vs CTRL and data are presented as mean \pm SE from three experiments. * p < 0.01, **p<0.05. (C) Apoptotic cell death in U251 cells was confirmed by Hoechst 3324 staining (n = 3 separate experiments). (D) Enzymatic caspase 3 and caspase 8 activation in GBM cells after treatment with RT, PBI-05204 and RT + PBI-05204 for 24 hr (n = 3 separate experiments). Data are shown as mean \pm SE. **p< 0.01. (E) Cell cycle analysis of U87MG and T98G cells treated with RT, PBI-05204 and RT plus PBI-05204 for 24 hrs.



Figure S4. The tumor growth curve of U251 (A) and T98G (B) mouse xenografts after being treated with RT alone, PBI-05204 alone or RT plus PBI-05204. The detailed treatment schedule was described in M&M section. Data are presented as mean \pm SD.